Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is Manager of Event & Health Communications, working on communications for BIO’s events and health care policy issues. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He recently completed a Master’s degree in communications at Georgetown University.

Latest Posts

BIO’s Dave Thomas Talks VC Funding with Daniel Levine

72263479

Last week, BIO Industry Analysis’s Dave Thomas spoke with Daniel Levine for his weekly podcast, The Bio Report. Dave discussed BIO‘s Venture Funding of Therapeutic Innovation Report, of which he is the lead author. The report analyzes data from four venture capital databases – Thomson Reuters, BioCentury, Elsevier, and Evaluate Pharm – to investigate investor trends, examine investment in specific therapeutic areas and indications, and identify disease areas that might be struggling for early-stage venture Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

GEN Ranks Top Ten U.S. Biopharma Clusters

BIO-InternationalConvention_Graphic_115x176_v3

Yesterday, Alex Philippidis at Genetic Engineering and Biotechnology News released their annual ranking of the top 10 U.S. biopharma clusters. To rank the clusers, five criteria are considered: NIH funding, venture capital funding, number of biotech patents awarded, lab space, and jobs. Landing the number 6 spot is the Greater Philadelphia region, home to this year’s BIO International Convention. From the report: The birthplace of independence saw a nice year-over-year increase in venture capital financing, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Getting Ready for #RDD2015 (Rare Disease Day 2015)

RDD_white

Rare Disease Day is just around the corner on February 28th. R&D investment into rare disease research by venture capitalists was a major focus of BIO’s recent Venture Funding of Therapeutic Innovation between 2004-2013, available for download here. One of the more interesting findings in the study is the large increase of funding by venture capitalists for rare disease R&D over the past decade, as this chart illustrates: Over the last 10 years, there has Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Deal Structures: More Options for Companies

CEO2013_115x75_Thumbnail copy

By most measures, 2014 was a great year for the biotechnology industry. Venture capital deal values, , licensing values and volume were all up, as were big pharma M&A deals and asset swaps. What do these trends mean for dealmakers in 2015? Answering that question was the task of a panel at the 2015 BIO CEO & Investor Conference, Emerging Trends in Deal Structures. Moderated by Fenwick and West’s Effie Toshav, the panel included: Bruce Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Getting Ahead of Ebola and Other Infectious Threats—Overturning Assumptions

ebola

Ebola was one of the biggest stories of 2014 (with Ebola fighters named the TIME Person of the Year), and the epidemic has led to renewed interest from governments and philanthropies to tackle the problem of emerging infectious diseases. To discuss the lessons learned and new approaches being taken in light of the Ebola crisis, BIO hosted a panel today at the 17th Annual BIO CEO & Investor Conference here in New York, moderated by Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,